Skip to main content
NEUROTECH INTERNATIONAL LIMITED logo

NEUROTECH INTERNATIONAL LIMITED — Investor Relations & Filings

Ticker · NTI ISIN · AU000000NTI9 ASX Professional, scientific and technical activities
Open in API
Filings indexed 667 across all filing types
Latest filing 2021-10-28 Interim / Quarterly Rep…
Country AU Australia
Listing ASX NTI

About NEUROTECH INTERNATIONAL LIMITED

https://neurotechinternational.com/

Neurotech International Limited is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for neurodevelopmental and neurological disorders. The company specializes in neuroprotective therapies, primarily targeting pediatric conditions with significant unmet medical needs, including Autism Spectrum Disorder (ASD), Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS), and Pediatric Acute-onset Neuropsychiatric Syndrome (PANS). Its lead drug candidate, NTI164, is a proprietary, broad-spectrum cannabinoid formulation derived from a unique cannabis strain. NTI164 is engineered to exert anti-inflammatory and neuroprotective effects by modulating neuroinflammatory pathways. The company conducts clinical trials to establish the safety and efficacy of its treatments, aiming to provide transformative behavioral and functional improvements for patients.

Recent filings

Filing Released Lang Actions
Quarterly Activities/Appendix 4C Cash Flow Report 10 pages 1.6MB
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "Quarterly report for the period ended 30 Sept 2021" and contains detailed operational and financial information for the quarter, including research updates, clinical study progress, patent filings, and a cash flow statement (Appendix 4C). The presence of substantive financial data such as cash flows, operating expenses, and director fees confirms it is a comprehensive quarterly financial report rather than a brief announcement or presentation. The document length (15,000 characters) and detailed content further support this classification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q1 2022
2021-10-28 English
NTI to Present at the South-West Connect ASX Showcase 1
Investor Presentation Classification · 90% confidence The document is an ASX announcement dated 25 October 2021 about Neurotech International Limited's Chairman presenting at an upcoming ASX showcase event. It describes the presentation content and provides event registration details. There is no financial data, no report attached or referenced as being published, and no regulatory or legal filings. The document is a company presentation announcement for an investor event, not the presentation itself or a financial report. Therefore, it fits best as an Investor Presentation (IP) announcement, as it focuses on company strategy and clinical study updates for investors.
2021-10-24 English
Investor Presentation 15 pages 834.2KB
Investor Presentation Classification · 95% confidence The document is titled 'Investor Webinar Presentation' and contains detailed information about the company's business, products, market, board members, and scientific studies. It includes forward-looking statements, disclaimers, and corporate overview data. The content is structured as a presentation aimed at investors, focusing on company strategy, product pipeline, and market opportunity rather than formal financial statements or regulatory disclosures. There is no indication that this is an official annual or quarterly report, audit report, or earnings release. It is not a transcript of a call, nor a legal or governance filing. The document is clearly a presentation prepared for investors, consistent with the definition of an Investor Presentation (IP). The length (15,000 characters) and detailed content support this classification with high confidence.
2021-10-24 English
Successful Completion of Preclinical MS Studies 4 pages 256.0KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 22 October 2021 from Neurotech International Limited. It details the successful completion of preclinical studies on a proprietary medical cannabis strain (NTI164) for Multiple Sclerosis (MS). The content focuses on scientific study results, market potential, and future development opportunities. There are no financial statements, regulatory certifications, voting results, or management changes. The document is a corporate announcement about research progress and product development rather than a financial report or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. The document is a company announcement about research and development progress, which is best classified as a general Regulatory Filing (RNS) because it is a regulatory announcement made to the stock exchange (ASX) but does not fit other specific categories.
2021-10-21 English
Notice of Annual General Meeting/Proxy Form 32 pages 1.0MB
AGM Information Classification · 100% confidence The document is a Notice of Annual General Meeting (AGM) and Proxy Form for Neurotech International Limited dated 19 October 2021. It includes details about the AGM date, location, voting procedures, and the agenda items to be considered at the meeting, such as receiving the Annual Report, approving the Remuneration Report, election of directors, and other shareholder resolutions. The document is clearly a meeting notice and proxy solicitation material rather than the actual Annual Report or other financial filings. It is not a transcript, earnings release, or other report type. Therefore, the document fits the category of AGM Information (AGM-R). The document length (15,000 characters) and content confirm it is a full AGM notice and proxy form, not just a brief announcement or regulatory filing.
2021-10-18 English
Annual Report (Typeset) 88 pages 2.7MB
Annual Report Classification · 100% confidence The document is titled '2021 Annual Report' and contains detailed sections typical of an annual report, including Directors' Report, Auditor's Independence Declaration, Corporate Governance, Consolidated Financial Statements, Notes to the Financial Statements, Directors' Declaration, and Independent Audit Report. It covers the full financial year ended 30 June 2021, includes comprehensive financial data, operational review, and governance information. The length is substantial (15,000 characters), indicating it is the full report rather than an announcement or summary. Therefore, this document fits the definition of an Annual Report (10-K). FY 2021
2021-10-18 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.